Cogent Biosciences Inc (COGT)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Cogent Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 38.90 $ — 90% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 3,549.7% passed
- Share count grows by less than 3% a year 4.8% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 648 m net cash passed
- Operating cash flow covers the profits of the last three years 151 m failed
- Return on capital at 15% or higher, or up versus two years ago -38.2% failed
- Insiders hold at least 10% or are net buyers 0.4% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 39.5% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.26 | -2.70 – -1.96 | 10 | -6.8% | 10 |
| 12/31/2027 | -0.94 | -2.26 – 1.29 | 349 | 58.1% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.55 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.61 | – | 4 | -23.20 | -1,582.60 | -61 | -61 |
| 2025: Q1 | -0.64 | – | 0 | – | – | -67 | -67 |
| 2025: Q2 | -0.64 | – | 0 | – | – | -55 | -55 |
| 2025: Q3 | -0.71 | – | 0 | – | – | -64 | -64 |
| 2025: Q4 | -1.52 | – | 0 | -100.00 | – | -79 | -80 |
| 2026: Q1 | -1.44 | – | 0 | – | – | -87 | -87 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 6 | -19 | -18 | -2.45 | -19 | 52 | 76 |
| 2017 | 8 | -26 | -25 | -3.45 | -26 | 28 | 49 |
| 2018 | 10 | -36 | -35 | -5.55 | -32 | 60 | 86 |
| 2019 | 23 | -32 | -30 | -3.97 | -42 | 32 | 49 |
| 2020 | 8 | -82 | -75 | -6.75 | -36 | 235 | 251 |
| 2021 | 0 | -76 | -72 | -1.87 | -59 | 214 | 232 |
| 2022 | 0 | -148 | -133 | -2.26 | -119 | 256 | 301 |
| 2023 | 0 | -208 | -192 | -2.42 | -154 | 258 | 313 |
| 2024 | 0 | -276 | -256 | -2.46 | -208 | 256 | 328 |
| 2025 | 0 | -333 | -329 | -4.87 | -264 | 636 | 938 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Cogent Biosciences, Inc., ein Biotechnologieunternehmen im klinischen Stadium, konzentriert sich auf die Entwicklung von Präzisionstherapien für genetisch definierte Erkrankungen.
| Employees | 258 |
|---|---|
| Headquarters | Waltham, MA |
| Address | 275 Wyman Street, 02451 Waltham, United States |
| Phone | 617 945 5576 |
| Website | cogentbio.com |
| IPO Date | 29. Mar 2018 |
| ISIN | US19240Q2012 |
| Stock Split | 1:4 on 11/09/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Andrew R. Robbins M.B.A. | President, CEO & Director | 1976 |
| John L. Green C.A., CPA | CFO & Principal Accounting Officer | 1980 |
| John Edward Robinson Ph.D. | Chief Scientific Officer | 1974 |
| Jessica Sachs M.D. | Chief Medical Officer | 1975 |
| Cole Pinnow | Chief Commercial Officer | 1975 |
| Brad Barnett | Chief Technology Officer | – |
| Christi Waarich | Senior Director of Investor Relations | – |
| Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | 1980 |
| Abb Hayden | Senior Vice President of Sales | – |
| Erin Schellhammer | Chief People Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.